PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled

PepGen Inc.

• Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.
• Cash, equivalents and marketable securities $132.3M; funding seen into 2H 2027.
• FREEDOM2-DM1 5 mg/kg cohort showed favorable safety, splicing and vHOT trends; 10 mg/kg cohort fully enrolled with data expected 2H 2026.
• FDA partial clinical hold on FREEDOM2 relates to preclinical studies; timing of ongoing trial not impacted.
• 13 patients enrolled in open-label extension at 5 mg/kg with no discontinuations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.